• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>The Journal of Neurology and Psychopathology >Mesulergine in early Parkinsons disease: a double blind controlled trial.
【2h】

Mesulergine in early Parkinsons disease: a double blind controlled trial.

机译：帕金森氏病早期的美舒乐金：一项双盲对照试验。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The efficacy and tolerance of treatment with an 8-alpha-amino-ergoline derivative CU32-o85, Mesulergine, were compared with levodopa/benserazide (Madopar) in a 3 month double-blind controlled trial in 31 patients with Parkinson's disease, not previously treated with levodopa. The two treatments were equally well tolerated, and neither dyskinesias nor dose-related fluctuations developed. In 90% of the patients treated with Mesulergine, Parkinsonian symptoms improved, and at the dose given the overall therapeutical response was two-thirds that of levodopa. During further 9 months of open study the beneficial effect was maintained equally well in both groups. Compared with other dopamine agonists Mesulergine has a considerable antiparkinsonian effect. Unfortunately, further clinical evaluation of the compound recently has been stopped owing to sex and species specific histological alterations in rats. It is suggested that Mesulergine derivatives might well be of value in future treatment of early Parkinson's disease and of late incompensated stages.
机译：在一项未经治疗的31例帕金森氏病患者的为期3个月的双盲对照试验中，将8-α-氨基-麦角灵衍生物CU32-o85 Mesulergine与左旋多巴/苄丝肼（Madopar）的疗效和耐受性进行了比较与左旋多巴。两种疗法的耐受性相同，运动障碍和剂量相关波动均未发生。在90％的美舒乐宁治疗患者中，帕金森病症状有所改善，在给定剂量下，总治疗反应为左旋多巴的三分之二。在开放研究的另外9个月中，两组的有益效果均保持良好。与其他多巴胺激动剂相比，美舒乐宁具有相当大的抗帕金森病作用。不幸的是，由于大鼠中性别和物种特异性的组织学改变，最近该化合物的进一步临床评估已经停止。有人提出，美索拉金衍生物很可能在帕金森氏病早期和失代偿后期的治疗中具有价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号